{"entity":{"id":"nct06874335","kind":"trial","name":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of BHV-1530 run by Biohaven Therapeutics Ltd., now recruiting.","summary":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06874335 by Biohaven Therapeutics Ltd., with 140 participants planned, started 2025-03-20, primary completion expected 2029-03. Conditions recorded: Solid Tumor. Interventions recorded: BHV-1530, Cemiplimab.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06874335","url":"https://clinicaltrials.gov/study/NCT06874335"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["bhv-1530"],"companies":["biohaven"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06874335","phase":"1","setting":"A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors","sponsor":"Biohaven Therapeutics Ltd.","enrolled":140,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06874335/","neighbours":{"drug":[{"id":"bhv-1530","kind":"drug","name":"BHV-1530","route":"/drugs/bhv-1530/"}],"company":[{"id":"biohaven","kind":"company","name":"Biohaven","route":"/companies/biohaven/"}]}}